within Pharmacolibrary.Drugs.ATC.V;

model V09IX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 2.0,
    adminDuration  = 600,
    adminMass      = 0.37,
    adminCount     = 1,
    Vd             = 0.00028000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fludeoxyglucose (18F) is a radiopharmaceutical analog of glucose used primarily in positron emission tomography (PET) imaging for the assessment of glucose metabolism in tissues, especially in oncology, cardiology, and neurology. It is approved and widely used today as a diagnostic agent, not as a therapeutic drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult humans after standard intravenous administration for PET imaging.</p><h4>References</h4><ol><li>Brad Kline, Surekha Yadav, Youngho Seo, Robin Cumming Ippisch, Jessa Castillo, Rahul R Aggarwal, Robin Kate Kelley, Spencer C Behr, Robert R Flavell, Courtney Lawhn-Heath, Michelle Melisko, Hope S Rugo, Victoria Wang, Sue S Yom, Patrick Ha, Fei Jiang, Thomas A Hope,,Journal of nuclear medicine : official publication, Society of Nuclear Medicine,2024<a href='https://pubmed.ncbi.nlm.nih.gov/38697672/'>https://pubmed.ncbi.nlm.nih.gov/38697672/</a></li><li>Mohei M Abouzied, Elpida S Crawford, Hani Abdel Nabi,18F-FDG imaging: pitfalls and artifacts.,Journal of nuclear medicine technology,2005<a href='https://pubmed.ncbi.nlm.nih.gov/16145222/'>https://pubmed.ncbi.nlm.nih.gov/16145222/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09IX04;
